tbuckley/cabot-search huggingface dataset:
Abstract 5192: The mobilization and recruitment of bone marrow-derived stem cells contributes to the acceleration of tumor growth after surgery
Authors: Yoshihiro Takemoto, Tao-Sheng Li, Masayuki Kubo, Mako Ohshima, Kazuhiro Ueda, Eijirou Harada, Naomasa Uesugi, Tadahiko Enoki, Kimikazu Hamano
Journal: Cancer Research (2011)

Abstract Background. Although surgical resection of the primary tumor lesion is still the most promising strategy for cancer therapy, surgical injury may accelerate tumor growth and metastasis, negatively affecting patients’ prognosis. Previous studies have demonstrated that many factors, including the robust release of cytokines and temporal changes of immunological and inflammatory mediators may contribute to the acceleration of tumor growth and metastasis after surgery. However, the precise mechanisms are not yet fully understood. We tested the hypothesis that surgical injury induces mobilization and recruitment of bone marrow-derived stem cells, thereby enhancing angiogenesis and accelerating tumor growth. Methods. Mice were subjected to partial gastrectomy, and non-gastrectomized mice were used as controls. Mobilization of bone marrow stem cells was monitored after surgery. Using an established tumor model in GFP+ bone marrow-transplanted chimera mice, we further investigated whether the mobilized stem cells affected tumor growth. To evaluate the influence on tumor growth of surgical injury and the inhibition of SDF-1/CXCR4 signals, we used AMD3100, a CXCR4 antagonist. Results. Compared to control, gastrectomy significantly increased the populations of CD34+ cells (6.9±4.5% vs 3.3±0.4%, p&amp;lt;0.05) and CD34+/Flk-1+ cells (0.08±0.02% vs 0.05±0.01%, p&amp;lt;0.05) in peripheral blood 12 hours after surgery. Twelve days after surgery, the tumor volume was almost double in gastrectomized mice compared with control (580±106 mm3 vs 299±162 mm3, p&amp;lt;0.05). Histological analysis of tumor tissue revealed that the microvessel density and number of proliferating cells were significantly higher, but those of apoptotic cells were significantly lower, in gastrectomized mice as compared with control. Furthermore, the number of GFP+ cells found in tumor tissue was significantly larger in mice that underwent gastrectomy than in control. Some of the stained GFP+ cells were positive for CD34 and had been incorporated into microvessels. However, administration of AMD3100 significantly inhibited the recruitment of GFP+ cells and completely negated the acceleration in tumor growth after surgery (345±172 mm3, p&amp;lt;0.05). Conclusion. Surgical injury induces mobilization and recruitment of bone marrow stem cells, thereby enhancing angiogenesis and accelerating tumor growth. Temporary inhibition of the SDF-1/CXCR4 signals may represent new therapeutic strategies for preventing acceleration of tumor growth after surgery. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5192. doi:10.1158/1538-7445.AM2011-5192
Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation.
Authors: Y Yui, R Hattori, Y Takatsu, H Nakajima, A Wakabayashi, C Kawai, N Kayama, S Hiraku, T Inagawa, M Tsubojima
Journal: Circulation (1984)

The effect of the selective thromboxane A2 synthetase inhibitor OKY-1581, a pyridine derivative [sodium (E)-3-(4-(3-pyridylmethyl)phenyl)-2-methyl-2-propenoate], on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation was studied in human volunteers. To clarify its effectiveness as an enzyme inhibitor, OKY-1581, at doses of 17, 83, 167, 417, 833, and 1667 micrograms/kg (n = 5 for each group), was injected intravenously, or was infused (10 micrograms/kg/min; n = 5) over 3 hr on 3 successive days. OKY-1580 (OKY-1581 free acid) was rapidly converted to its main beta-oxidized product, OKY-1565, and its reduced form, OKY-1558. During the study, plasma thromboxane B2 levels, inhibition of thromboxane B2 production in serum, and inhibition of rabbit platelet thromboxane A2 synthetase were monitored continuously. Twenty-five minutes after the injection of the above doses, plasma thromboxane B2 levels decreased by 4 +/- 7%, 40 +/- 14%, 57 +/- 7%, 68 +/- 6%, 93 +/- 5%, and 96 +/- 5% (mean +/- SD), respectively. Thromboxane B2 production in serum was decreased by 2 +/- 8%, 70 +/- 10%, 75 +/- 8%, 81 +/- 10%, and 96 +/- 8%, respectively, and rabbit platelet thromboxane A2 synthetase by 2 +/- 7%, 52 +/- 8%, 79 +/- 10%, 80 +/- 9%, 96 +/- 8%, and 95 +/- 7%. These parameters returned to the control levels 24 hr after the injection.(ABSTRACT TRUNCATED AT 250 WORDS)
Correcting the Record on Dietary Supplement Regulation—Reply
Authors: Donald M. Marcus, Arthur P. Grollman
Journal: JAMA Internal Medicine (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Endoscopic Hemostasis in Exulceratio Simplex - Dieulafoy's Disease Hemorrhage: A Review of 25 Cases
Authors: P. Skok
Journal: Endoscopy (1998)

Dieulafoy's disease is a rare cause of upper gastrointestinal tract hemorrhage. The aim of the study was to evaluate the efficacy of endoscopic hemostasis and to analyze the mortality of patients with hemorrhage due to Dieulafoy's disease.The retrospective analysis included patients from our institution who had undergone urgent endoscopic examination of the upper digestive tract and hemostatic interventions in the period between January 1994 and December 1996.Twenty-five patients were examined (18 men and 7 women, average age 52.6, SD+/-15.3, range 25-78). In 20 patients endoscopic injection sclerotherapy was performed (diluted epinephrine 1:10,000 plus polidocanol 1%) and Nd:YAG laser photocoagulation in five patients. In all patients a total of 44 interventional endoscopies were carried out. Repeated endoscopic hemostasis did not prove successful in two patients (8%, 2 men), and they were treated operatively. During the postoperative period one patient died because of multiorgan failure. The total mortality rate of all patients in which endoscopic hemostasis was done was 16% (4/25). None of the 21 surviving patients had rebleeding on long-term follow-up (mean: 29.4 months).Endoscopic hemostasis is a major therapeutic advance in the management of Dieulafoy's disease hemorrhage. Interventional endoscopy has decreased the need for surgical management and significantly reduced mortality.
TCTAP A-031 The Impact of Angiographic Calcification on Five-Year Clinical Outcomes Following Left Main Coronary Artery Intervention with Drug-Eluting Stents
Authors: Shaopeng Xu, Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Jabar Ali, Harris Ngow, Ji Bak Kim, Cheol Ung Choi, Eung Ju Kim, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2015)
Routine Iron Supplementation and Screening for Iron Deficiency Anemia in Pregnancy: A Systematic Review for the U.S. Preventive Services Task Force
Authors: Amy G. Cantor, Christina Bougatsos, Tracy Dana, Ian Blazina, Marian McDonagh
Journal: Annals of Internal Medicine (2015)

Routine screening and supplementation for iron deficiency anemia (IDA) in asymptomatic, nonanemic pregnant women could improve maternal and infant health outcomes.Update of a 2006 systematic review by the U.S. Preventive Services Task Force on screening and supplementation for IDA in pregnancy.MEDLINE and the Cochrane Library (1996 to August 2014) and reference lists of relevant systematic reviews to identify studies published since 1996.English-language trials and controlled observational studies about effectiveness of screening and routine supplementation for IDA in developed countries.Data extraction and quality assessment confirmed and dual-rated by a second investigator using prespecified criteria.No study directly compared clinical outcomes or harms of screening or not screening pregnant women for IDA. Twelve supplementation trials were included, and no controlled observational studies met inclusion criteria. On the basis of 11 trials, routine maternal iron supplementation had inconsistent effects on rates of cesarean delivery, small size for gestational age, and low birthweight and no effect on maternal quality of life, gestational age, Apgar scores, preterm birth, or infant mortality. Twelve trials reported improvements in maternal hematologic indices, although not all were statistically significant. Pooled analysis of 4 trials resulted in a statistically significant difference in IDA incidence at term, favoring supplementation (risk ratio, 0.29 [95% CI, 0.17 to 0.49]; I2 = 0%). Maternal iron supplementation did not affect infant iron status at 6 months. Harms, none of which were serious or had long-term consequences, were inconsistently reported in 10 of the trials, with most finding no difference between groups.Data from trials in countries with limited generalizability to U.S. populations were included. Studies were methodologically heterogeneous, and some were small and underpowered.There is inconclusive evidence that routine prenatal supplementation for IDA improves maternal or infant clinical health outcomes, but supplementation may improve maternal hematologic indices.Agency for Healthcare Research and Quality.
Abstract MS1-3: Clinical Development of mTOR Inhibitors in Breast Cancer
Authors: F André
Journal: Cancer Research (2012)

Abstract mTOR is a serine/threonine kinase involved in cancer cell metabolism and protein synthesis. mTOR induces phosphorylation of estrogen receptor and resistance to endocrine therapy in preclinical models. Based on this rationale, clinical trials have evaluated whether first generation of mTOR inhibitors could reverse resistance to endocrine therapy. Two randomized trials, including one registration trial, have reported that everolimus improves progression-free survival in patients resistant to non-steroidal aromatase inhibitors. These data are consistent with a phase II randomized trial performed in the neoadjuvant setting. One large phase III trial performed with temsirolimus failed, mainly due to dose intensity of the drug and patient population. Overall, these finding suggest that rapalogs could reverse resistance to endocrine therapy. These data open several avenues in the field of breast cancer. First, two trials are starting that evaluate the efficacy of everolimus in the adjuvant setting. These trials evaluate everolimus either frontline or after 2–3 years of endocrine therapy. Second, rapalogs are being tested in other breast cancer subtypes including Her2-overexpressing breast cancers and triple negative breast cancers. Indeed, mTOR has been shown to be involved in trastuzumab resistance in preclinical studies. Early trials have suggested that mTOR inhibition could reverse trastuzumab resistance. mTOR inhibitors have also been shown to synergize with cisplatin in preclinical models, and this combination is currently being evaluated in a phase II randomized trial. Finally, several mechanisms of resistance to rapalogs have been identified. This includes positive feedback loops and lack of optimal bioactivity on p4EBP1. Rapalogs indeed mediate activating feedback loops that in turn induce a paradoxical activation of kinase pathways. Based on this observation, several trials have started that evaluate the combination between Rapalogs and IGF1R inhibitors. Preliminary results from phase I trial suggest that this combination is active in ER+/highly proliferative disease. Although they induce optimal inhibition of pS6K, several studies have reported that rapalogs could be suboptimal to inhibit p4EBP1, a protein downstream of mTORC1. 4EBP1 is involved in protein synthesis. Second generation mTOR inhibitors (mTORC1/C2 inhibitors) present an increased bioactivity on 4EBP1, in addition to avoid mTORC2-mediated feedback loop. This second generation mTOR inhibitor is being tested in early phase trials. Overall, rapalogs have opened the path for the development of mTOR inhibitors in the field of breast cancer. This will further improve outcome by exploring new indications and by developing strategies to reverse resistance. Finally, the development of mTOR inhibitors will dramatically increase our knowledge on the role of metabolism and protein translation in cancer progression. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr MS1-3.
Expression of Trypsinogen-1, Trypsinogen-2, and Tumor-Associated Trypsin Inhibitor in Ovarian Cancer
Authors: Annukka Paju, Juhani Vartiainen, Caj Haglund, Outi Itkonen, Kristina von Boguslawski, Arto Leminen, Torsten Wahlström, Ulf-Håkan Stenman
Journal: Clinical Cancer Research (2004)

Abstract Purpose: The purpose is to study the prognostic significance of tissue expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor (TATI) and serum concentration of trypsinogen-2, trypsin-2-API (complex of trypsin-2 with α-1-proteinase inhibitor), and TATI in epithelial ovarian cancer. Experimental Design: Expression of trypsinogen-1, trypsinogen-2, and TATI was determined by immunohistochemistry with monoclonal antibodies in tissue sections of tumors from 119 patients with untreated primary epithelial ovarian cancer. Preoperative serum concentrations of trypsinogen-2, trypsin-2-API and TATI were analyzed using specific immunoassays. Results: Fifty-four percent of the tumors expressed trypsinogen-1, 45% expressed trypsinogen-2, and 30% expressed TATI. In patients with stage III and IV disease, TATI tissue expression (P = 0.002) and elevated TATI concentration in serum (P = 0.048) were associated with adverse cancer-specific and progression-free survival in univariate analysis. In multivariate analysis, TATI tissue expression (P = 0.005), tumor grade (P = 0.0001), histological type (P = 0.02), and stage (P = 0.0005) were independent prognostic factors for adverse cancer-specific survival and TATI tissue expression (P = 0.006) and grade (P = 0.0003) for progression-free survival. In multivariate analysis of all patients and those with advanced disease, serum trypsin-2-API concentration was an adverse prognostic factor for cancer-specific and progression-free survival, and it was independent of stage and histological type of the tumor (P ≤ 0.01). Conclusions: Tissue expression of TATI and an elevated preoperative serum concentration of trypsin-2-API are strong independent prognostic factors in advanced epithelial ovarian cancer. These results suggest that trypsin expression plays a role in the progression of ovarian cancer. TATI and trypsin-2-API are of potential use as an aid for stratification of randomized studies and for selecting treatment strategies.
Fixed drug eruption due to ciprofloxacin
Authors: S. DHAR, V. K. SHARMA
Journal: British Journal of Dermatology (1996)

We describe seven patients with fixed drug eruption (FDE) due to ciprofloxacin, five confirmed by rechallenge. These cases make up 8.75% of all cases of FDE seen by us during 1992-93. Isolated, and striking involvement of the lips was seen in two patients. To our knowledge, only a single case of FDE to ciprofloxacin previously has been reported. Our experience suggests that, with widespread use, ciprofloxacin could become one of the common drugs causing FDE.
ESR of copper and iron complexes with antitumor and cytotoxic properties.
Authors: W E Antholine, B Kalyanaraman, D H Petering
Journal: Environmental Health Perspectives (1985)

The relatively few iron and copper metal complexes which have been examined in cells and tissues for their redox properties, radical generation properties, and antitumor activity are discussed for studies which utilized electron spin resonance spectroscopy (ESR). A common property of a number of metal complexes, which include bleomycin, adriamycin, and thiosemicarbazones described in this review, is that they are readily reduced by thiol compounds and oxidized by oxygen or reduced species of oxygen to produce radicals. Structural features of these reactions are identified by ESR spectroscopy in model systems and often in cells. Furthermore, ESR spectroscopy has been most useful to probe the environment of the complexes in cells and to measure the rate of reduction of their oxidized forms. As a result of these studies, it is anticipated that more attention will be given to the exploration of redox-active metal complexes as drugs.
Reply to “Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer)” by L. Del Mastro et al. (Ann Oncol 2005; 16: 253–258)
Authors: C.H. Smorenburg, A.J. ten Tije
Journal: Annals of Oncology (2005)

As only few studies have investigated the efficacy and feasibility of chemotherapy in elderly cancer patients, the study by Del Mastro et al. [1.Del Mastro L. Perrone F. Repetto L. et al.Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer).Ann Oncol. 2005; 16: 253-258Abstract Full Text Full Text PDF PubMed Scopus (70) Google Scholar] on weekly paclitaxel in elderly breast cancer patients is of relevance for clinical daily practice. Their results, with a response rate of 53.7% (intention-to-treat 48%), are in a similar range to a response rate of 38% (intention-to-treat 38%) in our study using a similar weekly schedule of paclitaxel as first-line chemotherapy in 26 elderly patients with metastatic breast cancer [2.ten Tije A.J. Smorenburg C.H. Seynaeve C. et al.Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer.Eur J Cancer. 2004; 40: 352-357Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar]. In contrast to the high rate of cardiovascular complications reported by Del Mastro et al., we did not observe any cardiovascular toxicity, although we did not perform routine MUGA (multigated acquisition) or echocardiographic evaluation, and therefore may have missed any asymptomatic impairment of ejection fraction. The difference in toxicity cannot be explained by age: the median age of patients in the study by Del Mastro was 74 years as compared with 77 years in our study. As 24 out of 46 patients (52%) in the study by Del Mastro et al. received previous (neo-)adjuvant chemotherapy, while none of our patients had been pretreated with chemotherapy, we wonder whether the cardiovascular complications may have been correlated to pretreatment with anthracyline chemotherapy.
Rehabilitation of the Coronary Patient
Authors: Charles Long
Journal: JAMA (1985)

Two of the most effective voices in cardiac rehabilitation combine again in a second edition of their already classic<i>Rehabilitation of the Coronary Patient</i>. The 1978 predecessor of this book was a multiauthored introduction to the history and state of the art of cardiac rehabilitation as seen by some of its major proponents. The second edition is an expanded work of greater depth and breadth. Partially modified versions of the original chapters take the reader through the basic physiology and morphology and then the gamut of the rehabilitation process, from onset of infarction, through education of the patient and family, to the design and implementation of individual and collective exercise programs. The unsettled nature of some of the aspects of primary and secondary prevention in coronary artery disease are reflected thoughtfully and neutrally throughout the book. One feels the authors' frustration at the lack of clear, statistically significant evidence of
The efficacy of patellar taping in individuals with patellofemoral pain syndrome: a systematic review
Authors: V Balachandar, C Barton, D Morrissey
Journal: British Journal of Sports Medicine (2011)

Pain reduction through patella taping has been hypothesised to be achieved via changes to neuromuscular control and/or patellofemoral joint (PFJ) kinematics. Considering the high number of recent publications, a systematic review and meta-analysis evaluating the effects of patellar taping on pain, neuromuscular control and PFJ kinematics is warranted. MEDLINE, CINAHL, SPORTDiscus, Google Scholar, Web of Science, and EMBASE databases were searched from inception until February 2011 for randomised studies evaluating the effects of patellar taping on pain, neuromuscular control, and/or PFJ kinematics in individuals with PFPS. All potential publications were assessed by 2 independent reviewers for inclusion and quality using the Downs and Black Quality Index. Ten studies were included for final review. Two studies investigated medium to longer term effects of taping on pain (4 to 52 weeks), and eight studies investigated the immediate effects of taping on pain, neuromuscular control, and/or PFJ kinematics. Effect size calculations showed that perceived pain was reduced at four weeks by medially directed taping in combination with exercise. In the immediate term, medially directed patellar taping reduced pain during functional tasks. Patellar taping was found to reduce vastus medialis (VMO) to vastus lateralis (VL) ratio, and produce earlier vastus medialis oblique (VMO) activation. Patellar taping provides an effective means of pain relief in PFPS in the immediate term. Additionally, further high quality randomised trials with long term follow-up evaluating the efficacy of patellar taping as an adjunct or alternative treatment to other evidence based interventions is needed. Possible neuromuscular mechanisms behind patellar taping efficacy may be reduced levels and earlier onsets of VMO activity. There is a paucity of research evaluating the effects of patellar taping on PFJ kinematics.